Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10813872
Filing Date		2004-03-30
First Named Inventor Domi		nique Charmot
Art Unit		1618
Examiner Name Micah		Paul Young
Attomacy Dooket Number		II DS 04034 403

				Attorney Docket Number		ILPS 04031.102					
					IIS	PATENTS			Remove		
					0.0.			Τ.			_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	ssue Date Name of Patentee or Applicant Relev		Releva	s,Columns,Lines where ant Passages or Relevant es Appear			
	1										
If you wish	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P.	ATENT	APPLK	CATION PUBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion			nt Passaç	Lines where ges or Relev		
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ar	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cite Document	tentee or where I		or Relevant	TE
	1	0349453	EP		A1	1989-04-21	Martani et al.				
	2	0040224	wo			2000-07-13	Cumming et al.				
If you wish	h to a	dd additional Foreign P	atent Do	cument	l citation	information pl	ease click the Ad	d button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		10813872
ing Date		2004-03-30
st Named Inventor Domin		nique Charmot
t Unit		1618
aminer Name Micah		Paul Young
tornev Docket Number		ILPS 04031.102

Examiner Initials*	amine Cite No No Repair (CAPITAL ETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					
	1	UNA, M. et al., Controlled-release liquid suspensions based on ion-exchange particles entrapped within acrylic icrocapusies, International Journal of Pharmacoulics, 2000, Vol. 199, pp. 151-158, Elsevier Science				
	2	CHIKAWA, H. et al., Use of lon-exchange resins to prepare 100 µm-szed microcapsules with protonged drug-release y the Wurster process, International Journal of Pharmaceutics, 2001, Vol. 216, pp. 67-76, Eisevier Science				
	3	P Search Report for counterpart foreign Application No. 05731099 dated May 8, 2007, 3 pages				
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add				
		EXAMINER SIGNATURE				
Examiner	Signa	re Date Considered				
*EXAMIN	ER: In	al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a				

Fil

E)

See Kno Codes of USPTO Peter Documents at wave USETO.QDLY or MEEP 901.04. \* Enter of this flat issued the document, by the locations code (MPD) Searched 310, \*\*See Compress peter for counters, the a rodication of the year of the insight of the Emperor many precede the settle number of the patent document. \*Secretary of the Counter by the appropriate symbols as indicated on the document under WIPO Standard 51.16 if possible. \* Applicant is to place a check mark here if English imprisuse treatment in a standard.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10813872
	Filing Date		2004-03-30
	First Named Inventor	Domi	nique Charmot
	Art Unit		1618
	Examiner Name	Micah	Paul Young
	Attorney Docket Number		ILPS 04031.102

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a design patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 1.57(c) and the contraction of the contraction

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Janet S. Hendrickson/	Date (YYYY-MM-DD)	2007-06-11
Name/Print	Janet S. Hendrickson	Registration Number	55258

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients of the patients of the patients of the patients and the principal patients are patients. The principal patients are principally as a patient of the patients are principally as a patient of the patients are patients.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.